Abstract
The scarcity of human cadaver islets for transplantation in patients with Diabetes Mellitus (DM) has necessitated the search for alternative islet sources. With advancing islet biology research, Islet-Like Clusters (ILCs) derived from stem cells have demonstrated potential for treating DM and in novel drug discovery programs for drug and cytotoxicity testing. In vitro differentiation of ILCs from stem cells also provides an opportunity to mimic the in vivo islet developmental pathways. In vitro derived ILCs are often considered immature as they do not respond to glucose challenges efficiently. However, the in vitro and in vivo performance of ILCs can be improved by pharmacological preconditioning. In this review, we discuss how ILCs generated from human postnatal tissues can be utilized as an in-vitro model to study cytotoxicity, drug screening and enhancement of transplantation efficacy. The use of human cadaver islets is not permitted for research purposes in India. Under these restrictions, the application of ILCs in drug screening and their role in complementing, reducing, and replacing animal testing will evolve as a reliable platform for in vitro screening as well as for stem cell-based treatment in DM.
Keywords: Diabetes mellitus, drug screening, glucose responsiveness, islet like cluster, insulin secretion, islet transplantation.
Current Diabetes Reviews
Title:Human postnatal Mesenchymal Stem Cell Derived Islets as a Model for Diabetes Research
Volume: 17 Issue: 5
Author(s): Avinash Kharat, Bhawna Chandravanshi, Avinash Sanap, Supriya Kheur and Ramesh Bhonde*
Affiliation:
- Regenerative Medicine Laboratory, Dr. D. Y. Patil Dental College & Hospital, Dr. D. Y. Patil Vidyapeeth, Pimpri, Pune,India
Keywords: Diabetes mellitus, drug screening, glucose responsiveness, islet like cluster, insulin secretion, islet transplantation.
Abstract: The scarcity of human cadaver islets for transplantation in patients with Diabetes Mellitus (DM) has necessitated the search for alternative islet sources. With advancing islet biology research, Islet-Like Clusters (ILCs) derived from stem cells have demonstrated potential for treating DM and in novel drug discovery programs for drug and cytotoxicity testing. In vitro differentiation of ILCs from stem cells also provides an opportunity to mimic the in vivo islet developmental pathways. In vitro derived ILCs are often considered immature as they do not respond to glucose challenges efficiently. However, the in vitro and in vivo performance of ILCs can be improved by pharmacological preconditioning. In this review, we discuss how ILCs generated from human postnatal tissues can be utilized as an in-vitro model to study cytotoxicity, drug screening and enhancement of transplantation efficacy. The use of human cadaver islets is not permitted for research purposes in India. Under these restrictions, the application of ILCs in drug screening and their role in complementing, reducing, and replacing animal testing will evolve as a reliable platform for in vitro screening as well as for stem cell-based treatment in DM.
Export Options
About this article
Cite this article as:
Kharat Avinash , Chandravanshi Bhawna , Sanap Avinash , Kheur Supriya and Bhonde Ramesh *, Human postnatal Mesenchymal Stem Cell Derived Islets as a Model for Diabetes Research, Current Diabetes Reviews 2021; 17 (5) : e101220189128 . https://dx.doi.org/10.2174/1573399817999201214224559
DOI https://dx.doi.org/10.2174/1573399817999201214224559 |
Print ISSN 1573-3998 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6417 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Endothelial Glycocalyx as a Key Mediator of Albumin Handling and the Development of Diabetic Nephropathy
Current Vascular Pharmacology Bamboo a Supplement to Human Health: A Comprehensive Review on its Ethnopharmacology, Phytochemistry, and Pharmacological Activity
The Natural Products Journal Biochemical Markers of Renal Function
Current Medicinal Chemistry Pathophysiology of Contrast-Induced Acute Kidney Injury (CIAKI)
Current Pharmaceutical Design Diabetes Mellitus and Renal Function: Current Medical Research and Opinion
Current Diabetes Reviews The Pleiotropic Effects of ARB in Vascular Endothelial Progenitor Cells
Current Vascular Pharmacology The Association of Transcription Factor 7 like 2 Gene Polymorphism with Diabetic Nephropathy in Patients with Type 2 Diabetes Mellitus
Current Diabetes Reviews NGAL is a Precocious Marker of Therapeutic Response
Current Pharmaceutical Design Lipid Disorders in Diabetes Mellitus and Current Management
Current Pharmaceutical Analysis Chelating Agents for Metal Intoxication
Current Medicinal Chemistry Autocrine and Paracrine Secretion of Vascular Endothelial Growth Factor in the Pre-Hypoxic Diabetic Retina
Current Diabetes Reviews Vitamin D Replacement and Type 2 Diabetes Mellitus
Current Diabetes Reviews MicroRNAs: Biomarkers for Cardiovascular Disease in Patients with Diabetes Mellitus
Current Topics in Medicinal Chemistry Anderson-Fabry Disease: A Multiorgan Disease
Current Pharmaceutical Design Role of Advanced Glycation End Products (AGEs) and Oxidative Stress in Diabetic Retinopathy
Current Pharmaceutical Design Renal Sodium-Dependent Glucose Cotransporter 2 (SGLT2) Inhibitors for New Anti-Diabetic Agent
Current Topics in Medicinal Chemistry Diabetic Vascular Complications: Pathophysiology, Biochemical Basis and Potential Therapeutic Strategy
Current Pharmaceutical Design Hypertension in Hemodialysis Patients
Current Hypertension Reviews Editorial (Thematic Issue: Immunophilins, Protein Chemistry and Cell Biology of a Promising New Class of Drug Targets – Part II)
Current Molecular Pharmacology Advanced Glycation End Products and Insulin Resistance
Current Pharmaceutical Design